These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 22486168)
21. Split stoma in resectional surgery of high-risk patients with ileocolonic Crohn's disease. Myrelid P; Söderholm JD; Olaison G; Sjödahl R; Andersson P Colorectal Dis; 2012 Feb; 14(2):188-93. PubMed ID: 21689286 [TBL] [Abstract][Full Text] [Related]
22. Anastomotic leakage after lower gastrointestinal anastomosis: men are at a higher risk. Lipska MA; Bissett IP; Parry BR; Merrie AE ANZ J Surg; 2006 Jul; 76(7):579-85. PubMed ID: 16813622 [TBL] [Abstract][Full Text] [Related]
23. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn's disease. Myrelid P; Olaison G; Sjödahl R; Nyström PO; Almer S; Andersson P Dis Colon Rectum; 2009 Aug; 52(8):1387-94. PubMed ID: 19617749 [TBL] [Abstract][Full Text] [Related]
24. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid? Fascì Spurio F; Aratari A; Margagnoni G; Doddato MT; Papi C J Gastrointestin Liver Dis; 2012 Mar; 21(1):67-73. PubMed ID: 22457862 [TBL] [Abstract][Full Text] [Related]
25. The effect of immune therapy on surgical site infection following Crohn's Disease resection. Serradori T; Germain A; Scherrer ML; Ayav C; Perez M; Romain B; Palot JP; Rohr S; Peyrin-Biroulet L; Bresler L Br J Surg; 2013 Jul; 100(8):1089-93. PubMed ID: 23649458 [TBL] [Abstract][Full Text] [Related]
26. Certolizumab pegol for the management of Crohn's disease in adults. Rivkin A Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385 [TBL] [Abstract][Full Text] [Related]
27. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs. Krygier DS; Ko HH; Bressler B Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):407-15. PubMed ID: 19673627 [TBL] [Abstract][Full Text] [Related]
28. Determining Predictors for Intra-abdominal Septic Complications Following Ileocolonic Resection for Crohn's Disease-Considerations in Pre-operative and Peri-operative Optimisation Techniques to Improve Outcome. Morar PS; Hodgkinson JD; Thalayasingam S; Koysombat K; Purcell M; Hart AL; Warusavitarne J; Faiz O J Crohns Colitis; 2015 Jun; 9(6):483-91. PubMed ID: 25796553 [TBL] [Abstract][Full Text] [Related]
30. [Recurrence of Crohn's disease after surgery--causes and risks]. Mirow L; Hauenschild L; Hildebrand P; Kleemann M; Keller R; Franke C; Roblick UJ; Bruch HP; Kujath P Zentralbl Chir; 2008 Apr; 133(2):182-7. PubMed ID: 18415909 [TBL] [Abstract][Full Text] [Related]
31. Meningococcal meningoencephalitis after certolizumab pegol treatment in a patient with Crohn's disease. Majumder S; Kumar A J Crohns Colitis; 2013 Feb; 7(1):e19. PubMed ID: 22742971 [No Abstract] [Full Text] [Related]
32. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. Alves A; Panis Y; Bouhnik Y; Pocard M; Vicaut E; Valleur P Dis Colon Rectum; 2007 Mar; 50(3):331-6. PubMed ID: 17252288 [TBL] [Abstract][Full Text] [Related]
33. Risk factors for surgical site infection and association with infliximab administration during surgery for Crohn's disease. Uchino M; Ikeuchi H; Matsuoka H; Bando T; Ichiki K; Nakajima K; Tomita N; Takesue Y Dis Colon Rectum; 2013 Oct; 56(10):1156-65. PubMed ID: 24022533 [TBL] [Abstract][Full Text] [Related]
34. Intestinal Surgery for Crohn's Disease: Role of Preoperative Therapy in Postoperative Outcome. Scarpa M; Martinato M; Bertin E; Da Roit A; Pozza A; Ruffolo C; D'Incà R; Bardini R; Castoro C; Sturniolo GC; Angriman I Dig Surg; 2015; 32(4):243-50. PubMed ID: 25997472 [TBL] [Abstract][Full Text] [Related]
35. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors. Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418 [TBL] [Abstract][Full Text] [Related]
36. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Schreiber S; Colombel JF; Bloomfield R; Nikolaus S; Schölmerich J; Panés J; Sandborn WJ; Am J Gastroenterol; 2010 Jul; 105(7):1574-82. PubMed ID: 20234346 [TBL] [Abstract][Full Text] [Related]
37. The safety of biologic agents in the treatment of inflammatory bowel disease. Shepela C Minn Med; 2008 Jun; 91(6):42-5. PubMed ID: 18616021 [TBL] [Abstract][Full Text] [Related]